Three programs with clinical trial results in 2020 including OTIVIDEX™  Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO , Jan. 03, 2019 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative

Apply Now